|1.||Lu, William W: 7 articles (12/2013 - 09/2005)|
|2.||Li, Zhaoyang: 5 articles (01/2012 - 01/2009)|
|3.||Luk, Keith D K: 5 articles (06/2011 - 09/2005)|
|4.||D'Haese, Patrick C: 5 articles (01/2011 - 01/2003)|
|5.||Peng, Songlin: 4 articles (03/2014 - 01/2009)|
|6.||Pan, Haobo: 4 articles (03/2014 - 02/2011)|
|7.||De Broe, Marc E: 4 articles (03/2005 - 01/2003)|
|8.||Su, Wen-Ta: 3 articles (07/2015 - 08/2014)|
|9.||Zhou, Guangqian: 3 articles (03/2014 - 01/2009)|
|10.||Gelinsky, Michael: 3 articles (01/2014 - 01/2013)|
01/01/1997 - "In the view of these promising results and of the excellent tolerance of strontium during preliminary trials, additional investigations of this compound in prevention and treatment of osteoporosis should be promptly initiated. "
09/01/2005 - "Oral strontium has been shown to induce new bone formation and is effective in reducing fracture risk in osteoporosis. "
07/01/2004 - "Strontium: a new treatment for osteoporosis."
01/01/2014 - "Based on recent studies, strontium has been applied for osteoporosis treatment due to its positive effect on osteoblasts. "
10/15/2015 - "Strontium (Sr) has been shown to favor bone formation and is used clinically to treat osteoporosis. "
|2.||Neoplasm Metastasis (Metastasis)
04/01/2008 - "For the dose estimation of (89)Sr, a bone metastases model (GSF-M) was developed by adding a compartment, representing the metastases, into the strontium biokinetic model. "
04/01/2008 - "The objective of the present work is to apply the plasma clearance parameters to strontium, previously determined in our laboratory, to improve the biokinetic and dosimetric models of strontium-90 ((90)Sr) used in radiological protection; and also to apply this data for the estimation of the radiation doses from strontium-89 ((89)Sr) after administration to patients for the treatment of the painful bone metastases. "
04/01/2008 - "Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases."
01/01/2004 - "[Strontium-89 diagnosis and therapy of bone metastases]."
05/15/1995 - "[89-Strontium for painful osteoblastic metastases]."
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2001 - "Strontium 89 is currently the most commonly used radionuclide in the palliative management of prostate cancer metastatic to the skeleton. "
09/01/2008 - "[Strontium-89: a desirable therapeutic for bone metastases of prostate cancer]."
03/01/2010 - "[Strontium-89 for bone metastases from prostate cancer: an update]."
11/01/2000 - "Treatment with radioactive (89)strontium for patients with bone metastases from prostate cancer."
01/01/1991 - "The palliative efficacy of strontium-89 chloride has been evaluated in a prospective double-blind crossover study comparing it with stable strontium as placebo in 32 patients with prostate cancer metastatic to bone. "
05/01/1991 - "Topical varnish containing strontium in a sustained-release device as treatment for dentin hypersensitivity."
01/01/2013 - "The aim of the present paper was to review the published literature in order to identify all relevant studies for inclusion and to determine whether there was any evidence of the efficacy of strontium and potassium toothpastes in the treatment of dentine hypersensitivity (DH). "
01/01/2013 - "The efficacy of strontium and potassium toothpastes in treating dentine hypersensitivity: a systematic review."
02/01/1994 - "This study was a double-blind parallel group comparison of two strontium-based desensitizing toothpaste products and a conventional fluoride product in the treatment of dentine hypersensitivity. "
02/01/1994 - "Dentine hypersensitivity: a clinical trial to compare 2 strontium densensitizing toothpastes with a conventional fluoride toothpaste."
11/01/1994 - "About 60% to 90% of patients treated with strontium-89 respond with complete or partial relief of pain for a median duration of 6 months. "
02/17/1990 - "Strontium and bone pain."
10/01/1981 - "This suggests the possibility of using strontium to mineralize osteophenic areas and to relieve bone pain. "
10/01/2004 - "Patients treated with both external radiation and strontium had a positive correlation of 0.4 with a probability of P = 0.0158 between the responses to the 2 treatments, indicating that response to external radiotherapy could be viewed as an indicator of strontium-89 efficacy in metastatic osteoblastic bone pain palliation in the same patient. "
11/01/2003 - "In symptomatic HRPC, pain treatment with local field radiotherapy is associated with a better overall survival compared to Strontium(89). "
|2.||strontium ranelate (protelos)
|5.||Trace Elements (Biometals)
|8.||Parathyroid Hormone (Parathormone)
|9.||strontium chloride (strontium chloride Sr 89)
|3.||Renal Dialysis (Hemodialysis)
|5.||Continuous Ambulatory Peritoneal Dialysis (CAPD)